Our increasing knowledge of the mechanisms behind the progression of pancreatic cancer (PC) has not yet translated into effective treatments. Many promising drugs have failed in the clinic, highlighting the need for better preclinical models to assess drug efficacy and characterize mechanisms of resistance. Using different experimental models, including patient-derived xenografts (PDXs), we gauged the efficacy of therapies aimed at two hallmark lesions of PCs: activation of signaling pathways by oncogenic KRAS and inactivation of tumor-suppressor genes. Although the drug targeting inactivation of tumor suppressors by DNA methylation had little effect, the inhibition of Mek, a K-Ras effector, in combination with the standard of care (chemotherapy consisting of gemcitabine/Nab-paclitaxel), reduced the growth of three out of five PC-PDXs and impaired metastasis. The two least responding PC-PDXs were composed of genetically diverse cells, which displayed sensitivities to the Mek inhibitor differing by >10-fold. Unexpectedly, our analysis of this genetic diversity unveiled different KRAS mutations. As mutation in KRAS occurs early during progression, this heterogeneity may reflect the simultaneous appearance of different malignant cellular clones or, alternatively, that cells containing two mutations of KRAS are selected during tumor evolution. In vitro and in vivo analyses indicated that the intratumoral heterogeneity, along with the selective pressure imposed by the Mek inhibitor, resulted in rapid selection of resistant cells. Together with the gemcitabine/Nab-paclitaxel backbone, Mek inhibition could be effective in treatment of PC. However, resistance because of intratumoral heterogeneity is likely to develop frequently, pointing to the necessity of identifying the factors and mechanisms of resistance to further develop this therapy.
Subscribe to Journal
Get full journal access for 1 year
only $51.94 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ryan DP, Hong TS, Bardeesy N . Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 1039–1049.
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.
Hoff, Von DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691–1703.
Biankin AV, Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491: 399–405.
Collins MA, Bednar F, Zhang Y, Brisset J-C, Galbán S, Galbán CJ et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 2012; 122: 639–653.
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656–660.
Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM et al. A central role for RAF->MEK->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov 2012; 2: 685–693.
Weisenberger DJ . Characterizing DNA methylation alterations from the Cancer Genome Atlas. J Clin Invest 2014; 124: 17–23.
Missiaglia E, Donadelli M, Palmieri M, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR . Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005; 24: 199–211.
Kopetz S, Kopetz S, Lemos R, Lemos R, Powis G, Powis G . The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 2012; 18: 5160–5162.
Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE . Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009; 4: 1670–1680.
Fisher R, Pusztai L, Swanton C . Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108: 479–485.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 2017; 17: 254–268.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457–1461.
Gore J, Korc M . Pancreatic cancer stroma: friend or foe? Cancer Cell 2014; 25: 711–712.
Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu C-C, Simpson TR et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25: 719–734.
Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA et al. Stromal elements Actto restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014; 25: 735–747.
Van Cutsem E, Hidalgo M, Bazin I, Canon J-L, Poddubskaya E, Manojlovic N et al. Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer. J Clin Oncol 2015; 33; (Suppl3)Abstract 344.
Borroto A, Ruiz-Paz S, la Torre de TV, Borrell-Pages M, Merlos-Suarez A, Pandiella A et al. Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding. J Biol Chem 2003; 278: 25933–25939.
We thank Faye Su from Novartis and Daniel Pierce from Celgene for providing reagents and valuable insights. This work was supported by funds from the Instituto de Salud Carlos III (PI16/00253 and CIBER-ONC). KP was supported by the postdoctoral program from the AECC. FB was supported by the AGAUR-FI DGR-2014 predoctoral fellowship.
The authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Oncogene website
About this article
Cite this article
Pedersen, K., Bilal, F., Bernadó Morales, C. et al. Pancreatic cancer heterogeneity and response to Mek inhibition. Oncogene 36, 5639–5647 (2017). https://doi.org/10.1038/onc.2017.174
International Journal of Molecular Sciences (2020)
Technology in Cancer Research & Treatment (2020)
Journal of Pharmacy and Pharmacology (2019)
Nature Reviews Clinical Oncology (2019)
Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotype
Molecular Carcinogenesis (2019)